// OVERVIEW
Oorja Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Houston, Texas, focused on developing peptide-based therapies for fibrotic and cardiopulmonary diseases, with its lead asset ORJ-001 targeting idiopathic pulmonary fibrosis (IPF) by restoring alveolar epithelial type 2 cell function as a first-in-class β1 integrin agonist. The company raised $30 million in Series A financing and plans to initiate a Phase II trial in IPF patients before the end of 2026.
Discussed in
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
funding·StrictlyVC·MAY 23, 2026
“Raised $30M Series A for peptide-based therapies targeting lung disease.”
Source→02
mention·StrictlyVC·MAY 23, 2026
“Developing peptide-based therapies for fibrotic and cardiopulmonary diseases.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.